Zoetis Inc.
Zoetis
Zoetis Inc. is the world's leading pure-play animal health company, dominating the global veterinary pharmaceuticals and pet healthcare sector. Founded in 1952 as Pfizer's animal health division before its landmark IPO in 2013, Zoetis is headquartered in Parsippany, New Jersey, USA. With annual revenue of USD 9.467 billion (2025), the company operates 23 manufacturing sites across 11 countries, employing 14,000 employees worldwide. Zoetis commands an unparalleled 69% revenue concentration in companion animal products, powered by blockbuster franchises Simparica Trio and monoclonal antibody pain therapies Librela/Solensia.
Strengths:
• Absolute Market Dominance: Reigning global #1 with USD 95B revenue, unmatched scale across 120+ countries with 42.2B US companion animal revenue alone
• Biologics Manufacturing Supremacy: 23 fully owned manufacturing sites with $590M invested in a new Georgia mAb/vaccine facility and quadrupled capacity at Tullamore, Ireland
• Innovation Pipeline Leadership: Simparica Trio surpassed $10B in single-market US sales; Librela and Solensia remain the only approved NGF-targeting monoclonal antibodies for canine/feline OA pain
• Vertical Integration: Seamless R&D-to-commercial-production closed loop, with Kalamazoo serving as both global R&D HQ and largest manufacturing hub
• Regulatory & Scientific Authority: Over 70 country-level direct operations with deep relationships across FDA, EMA, and global veterinary regulatory bodies
Weaknesses:
• Single-Asset Manufacturing Risk: Complex biologics (mAbs) are produced at single dedicated facilities; any contamination or equipment failure risks localized supply disruptions
• Macroeconomic Sensitivity: Q1 2025 saw US companion animal demand softening due to reduced veterinary clinic visits amid consumer spending pressure
• Premium Pricing Vulnerability: Generic and biosimilar competition from emerging Asian manufacturers threatens long-term pricing power in price-sensitive marketsRead MoreShow Less
Strengths:
• Absolute Market Dominance: Reigning global #1 with USD 95B revenue, unmatched scale across 120+ countries with 42.2B US companion animal revenue alone
• Biologics Manufacturing Supremacy: 23 fully owned manufacturing sites with $590M invested in a new Georgia mAb/vaccine facility and quadrupled capacity at Tullamore, Ireland
• Innovation Pipeline Leadership: Simparica Trio surpassed $10B in single-market US sales; Librela and Solensia remain the only approved NGF-targeting monoclonal antibodies for canine/feline OA pain
• Vertical Integration: Seamless R&D-to-commercial-production closed loop, with Kalamazoo serving as both global R&D HQ and largest manufacturing hub
• Regulatory & Scientific Authority: Over 70 country-level direct operations with deep relationships across FDA, EMA, and global veterinary regulatory bodies
Weaknesses:
• Single-Asset Manufacturing Risk: Complex biologics (mAbs) are produced at single dedicated facilities; any contamination or equipment failure risks localized supply disruptions
• Macroeconomic Sensitivity: Q1 2025 saw US companion animal demand softening due to reduced veterinary clinic visits amid consumer spending pressure
• Premium Pricing Vulnerability: Generic and biosimilar competition from emerging Asian manufacturers threatens long-term pricing power in price-sensitive markets
Listed market data
ZTS · NYSE · weeklyHistory →- Market cap
- $32.8 B
- Share price
- USD 79.38
- 1Y change
- -44.9%
- Recent change
- -1.2%
- IPO price
- +211.7%
- Revenue (TTM)
- $9.5 B
10-22 → 10-23
USD 26.00 · from 2/01/2013
Financial history
Full market history- 2026-10USD 79.38$32.8 B+13.7%
- 2026-09USD 69.83$28.3 B-9.4%
- 2026-08USD 77.10$31.2 B-0.2%
- 2026-07USD 77.29$31.3 B+7.6%
- 2026-06USD 71.86$29.1 B-7.5%
- 2026-05USD 77.69$31.4 B-32.4%
- 2026-04USD 114.97$46.5 B-2.7%
- 2026-03USD 118.21$47.9 B-9.8%
- 2026-02USD 131.10$53.1 B+5.0%
- 2026-01USD 124.82$50.5 B-0.8%
- 2025-12USD 125.82$50.9 B-1.8%
- 2025-11USD 128.18$51.9 B—
In the press
All coverage →5 latest headlines- Zoetis: Weakening Fundamentals Overshadow The Discount (NYSE:ZTS) - Seeking Alphaseekingalpha.com2026-10-20
- Zoetis Inc. stock outperforms competitors on strong trading day - MarketWatchwww.marketwatch.com2026-10-16
- Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?finance.yahoo.com2026-10-16
- Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted? - Yahoo Financefinance.yahoo.com2026-10-16
- Zoetis Inc (ZTS) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 - GuruFocuswww.gurufocus.com2026-10-15
While Zoetis utilizes over 110 third-party CMOs for non-core edge processes, all mission-critical products—particularly complex biologics, monoclonal antibodies, and innovative vaccine platforms—are produced entirely within its proprietary, highly secured facilities. The Kalamazoo, Michigan site serves as both global R&D headquarters and largest manufacturing hub, enabling a seamless research-pilot-scale-commercial production closed loop.
In 2025, Zoetis invested $590 million in a new monoclonal antibody and vaccine manufacturing facility in Douglasville, Georgia, and completed a quadrupling of capacity at its Tullamore, Ireland plant.
• Parasiticides: Simparica Trio / Revolution Plus
• Dermatology: Apoquel / Cytopoint
• Pain Management: Librela / Solensia monoclonal antibodies
• Vaccines: Vanguard / Fel-O-Vax
• Anti-infectives and companion animal diagnostics
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $9.5 B | $2.7 B |
| 2024 | $9.3 B | $2.5 B |
| 2023 | $8.5 B | $2.3 B |
| 2022 | $8.1 B | $2.1 B |
| 2021 | $7.8 B | $2 B |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Parsippany, New Jersey, United States
Founded
1952
Employees
14,000
Revenue
USD$9.5 B (2025)
Market cap
$32.8 B
Factories
23 manufacturing sites across 11 countries
Presence
Products sold in 120+ countries, direct operations in 45+ countries
Listing
NYSE: ZTS
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website NYSE: ZTS , Zoetis Official Website
SEC EDGAR — Zoetis Filings
Wikipedia — Zoetis